Status:
COMPLETED
EVALUATION of the OVERALL HAEMOSTATIC CAPACITY of MIM8 with GLOBAL HAEMOSTASIS ASSAYS and FIBRIN CLOT ULTRASTRUCTURE
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Hemophilia a
Eligibility:
MALE
18-99 years
Brief Summary
Hemophilia A is an X linked disorder characterized by a deficiency in Factor VIII. The clinical hallmark of this disease is increased tendency to spontaneous bleeding with hemarthrosis accounting for ...
Eligibility Criteria
Inclusion
- Male patients,
- Age \> 18 years at time of inclusion
- Diagnosis of severe hemophilia A (FVIII \<2%)
- Severe hemophilia A (FVIII \<2%) and not receiving emicizumab prophylaxis
- Obtaining the patient's non-opposition
- Ability to comply with the study protocol, in the investigator's judgment
Exclusion
- Not willing to provide extra blood for the experiments
- Patients carrying the diagnoses of other coagulopathies in addition to hemophilia A
- Patients that have received any hemostatic agent within 5 half-lives of the blood draw.
Key Trial Info
Start Date :
March 28 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 4 2024
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT06212505
Start Date
March 28 2024
End Date
June 4 2024
Last Update
January 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de Référence Hémophilie, Hôpital Louis Pradel- Hospices Civils de Lyon
Bron, Rhone, France, 69500